相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
Helena Johansson et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
Can Change in FRAX Score Be Used to Treat to Target? A Population- Based Cohort Study
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures
Yohann Bala et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Assessment of Incident Spine and Hip Fractures in Women and Men Using Finite Element Analysis of CT Scans
David L. Kopperdahl et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image
Barbara C. Silva et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia et al.
EUROPEAN HEART JOURNAL (2013)
Goal-directed therapy in osteoporosis
Eugene McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Goal-directed treatment of osteoporosis
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Treat-to-target for Osteoporosis: Is Now the Time?
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Cholesterol limits lose their lustre
Heidi Ledford
NATURE (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle
K. Akesson et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Target cardiovascular risk rather than cholesterol concentration
Harlan M. Krumholz
BMJ-BRITISH MEDICAL JOURNAL (2013)
SCOPE: a scorecard for osteoporosis in Europe
J. A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Three Reasons to Abandon Low-Density Lipoprotein Targets An Open Letter to the Adult Treatment Panel IV of the National Institutes of Health
Rodney A. Hayward et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
Eugene V. McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
Matthew Austin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial
Meghan G. Donaldson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
Richard M. Jacques et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Does osteoporosis therapy invalidate FRAX for fracture prediction?
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis Results of a 2-year study
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Treatment failure in osteoporosis
A. Diez-Perez et al.
OSTEOPOROSIS INTERNATIONAL (2012)
A systematic review of hip fracture incidence and probability of fracture worldwide
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Has reimbursement of bone mineral density testing and anti-osteoporotic treatments improved management of osteoporosis in France?
F. Canoui-Poitrine et al.
BONE (2010)
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRA®
John A. Kanis et al.
BONE (2010)
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
P. Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture
Lee A. Jennings et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
Ren Rizzoli et al.
RHEUMATOLOGY INTERNATIONAL (2010)
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®
John A. Kanis et al.
BONE (2009)
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
P. Bergmann et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal
Alberto Zanchetti et al.
JOURNAL OF HYPERTENSION (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Theoretical implications of the biomechanical fracture threshold
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Histomorphometric and μCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate
Monique E. Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Olivier Bruyere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
How evidence-based are the recommendations in evidence-based guidelines?
Finlay A. McAlister et al.
PLOS MEDICINE (2007)
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Increases in BMD correlate with improvements in bone microarchitecture with Teriparatide treatment in postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Predictive value of BMD for hip and other fractures
O Johnell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Assessment of fracture risk
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
Peter Pietschmann
JOURNAL FUR MINERALSTOFFWECHSEL (2005)
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
JY Reginster et al.
BONE (2004)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis
R Marcus et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
YB Jiang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy
S Sarkar et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A method to assess the proportion of treatment effect explained by a surrogate endpoint
ZQ Li et al.
STATISTICS IN MEDICINE (2001)
Cardiovascular protection and blood pressure reduction: a meta-analysis
JA Staessen et al.
LANCET (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2001)
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
NH Bjarnason et al.
OSTEOPOROSIS INTERNATIONAL (2001)
Risk of hip fracture derived from relative risks: An analysis applied to the population of Sweden
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
